Denosumab in osteoporosis (Q38167352)

30 August 2017

title

Denosumab in osteoporosis (English)

1 reference

30 August 2017

0 references

Dima L Diab

1

1 reference

30 August 2017

Nelson B Watts

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

2 December 2013

1 reference

Expert Opinion on Drug Safety

30 August 2017

published in

1 reference

30 August 2017

volume

13

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

247-253

1 reference

A single-dose study of denosumab in patients with various degrees of renal impairment

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

The role of osteoprotegerin in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Severe symptomatic hypocalcaemia following a single dose of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Identification of the risk factors associated with hypocalcemia induced by denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

Effects of denosumab on fracture and bone mineral density by level of kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.860133

10.1517/14740338.2014.860133

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference